Clinical Trial Update: Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 study of NGM282 (Aldafermin) in patients with nonalcoholic steatohepatitis (NASH) has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• NGM282 (Aldafermin)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED | Results posted: 2025-06-26